CNBX Pharmaceuticals

About

Q&A

What is CNBX Pharmaceuticals' primary focus?

CNBX Pharmaceuticals is developing a platform that uses novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patient's specific profile.

Where is CNBX Pharmaceuticals headquartered?

CNBX Pharmaceuticals is headquartered in Tel Aviv-Yafo, Israel.

When was CNBX Pharmaceuticals founded?

CNBX Pharmaceuticals was founded in January 2004.

What is the current employee count for CNBX Pharmaceuticals?

CNBX Pharmaceuticals has 7 employees, falling within the 1-10 employee bucket.

What is CNBX Pharmaceuticals' current market capitalization?

CNBX Pharmaceuticals has a market capitalization of $221,585 USD.

Under what name does CNBX Pharmaceuticals operate in Israel?

CNBX Pharmaceuticals operates in Israel as G.R.I.N Ultra Ltd, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

What is the primary sector of CNBX Pharmaceuticals?

The primary sector for CNBX Pharmaceuticals is Health Tech & Life Sciences.

What is the product stage of CNBX Pharmaceuticals?

CNBX Pharmaceuticals is in the clinical trial product stage.

Team · 3

Eyal Ballan

Founder · Co-founder (No longer with the company)

Zohar Koren

Founder · Co-founder (No longer with the company)

Itamar Borochov

Founder · Co-founder (No longer with the company)

Sectors & technology

Tags